

CLAIM AMENDMENTS

1-12. (canceled)

13. (currently amended): A method of generating an immune response in a mammal by administering to the mammal a composition for the co-delivery to a cell of a nucleic acid and an assister protein, wherein the nucleic acid operatively encodes an antigenic protein or portion thereof which shares at least one epitope with the assister protein,

~~[[the]] which composition comprises liposomes consisting essentially of formed from liposome-forming materials and co-encapsulating said nucleic acid and said assister protein associated together and associated with liposomes formed from liposome forming materials, the liposomes having an average diameter in the range of 100-2000 nm, wherein~~

~~the antigenic protein and the assister protein are from an infectious-organism agent; said nucleic acid and said assister protein are both associated with the same liposomes; the nucleic acid is entrapped in the intravesicular space of the liposomes; [[and]] assister protein in antigenic form is displayed on the surface of the liposomes; the liposomes lack any further cell targeting moiety; the liposomes include at least one cationically charged component such that the liposomes have an overall positive charge;~~

~~the nucleic acid and the assister protein are present in a weight ratio in the range of 1000:1 to 1:1; and~~

~~the immune response comprises an antibody response specific to the antigenic protein or assister protein or both.~~

14-15. (canceled)

16. (currently amended): A method according to claim 13 wherein said infectious-organism-agent is an infectious virus.

17-24. (canceled)

25. (previously presented): A method according to claim 16 wherein the infectious virus is Hepatitis virus.

26. (previously presented): A method according to claim 13 in which the liposomes have an average diameter in the range of 100-400 nm.

27. (previously presented): The method of claim 13 wherein said liposomes lack phospholipids.

28. (previously presented): The method of claim 16 wherein the infectious virus is influenza virus.

29. (currently amended): A method to generate an immune response in a mammal which method comprises administering to said mammal via cutaneous injection a liposomal composition comprising liposomes consisting essentially of formed from liposome-forming materials and co-encapsulating a nucleic acid encoding an influenza hemagglutinin (HA) antigenic protein and a full-length influenza virus protein HA protein that shares at least one epitope with the encoded antigenic protein associated together and with liposomes in the composition;

wherein the nucleic acid is entrapped in the intravesicular space of the liposomes;
influenza HA protein in antigenic form is displayed on the surface of the liposomes;
the liposomes lack any further cell targeting moiety;
the liposomes include at least one cationically charged component such that the liposomes have an overall positive charge; and

wherein said method confers immunity against infection by the same type of influenza virus corresponding to said antigenic protein.

30. (previously presented): The method of claim 29 wherein the liposomes in said liposomal composition have an average diameter in the range of 100-2000 nm.

31. (new): The method of claim 13 wherein said liposome-performing components include phospholipids.